Neurovigen Transfers 'KDS2010' Technology with KIST... "Aiming to Enter the US Market This Year"

[Asia Economy Reporter Hyunseok Yoo] Neurobiogen announced on the 2nd that on December 30th last year, it held a technology transfer and joint research and development agreement ceremony with the Korea Institute of Science and Technology (KIST) for the development of central nervous system indication treatment drugs using 'KDS2010', a GABA overproduction inhibitor.

At this agreement ceremony, Neurobiogen announced plans for global new drug development through technology transfer of spinal cord injury and stroke treatment technologies, which have a very high unmet medical need worldwide, along with collaborative clinical trial research.

Neurobiogen verified the efficacy and therapeutic mechanism of spinal cord injury recovery through GABA overproduction inhibition via joint research with Dr. Ki-duk Park’s team and Dr. Chang-jun Lee’s team (currently at the Institute for Basic Science) at KIST, and Professor Hyun Ha’s team at Yonsei University College of Medicine. It was confirmed that in a spinal cord injury rat model, nerve cells in the spinal cord recovered after injury through treatment with the KDS2010 drug.

Additionally, with Professor Hyung-il Kim’s team at Gwangju Institute of Science and Technology, the rehabilitation treatment efficacy and therapeutic mechanism were verified in a stroke model. The company explained that the degenerated motor function of the animal model induced with stroke was significantly improved through rehabilitation training combined with drug administration, and recovery efficacy in the lesion area according to the therapeutic mechanism was also confirmed.

A company official stated, "Neurobio’s technology transfer is receiving great attention as it suggests the possibility of developing First-in-Class drugs for spinal cord injury and stroke by expanding indications following the currently developing Alzheimer’s dementia and co-developed obesity treatments." He added, "In particular, for spinal cord injury, development is underway aiming for early clinical trials and market entry through orphan drug approval from the U.S. Food and Drug Administration this year."

The two institutions plan to complete non-clinical trials of the therapeutic candidate drug in the first half of this year through collaborative research, and after completing safety pharmacology tests, will proceed with clinical trials in 2020.

Meanwhile, Synergy Innovation recently invested in Neurobiogen together with Synergy Partners. Synergy Partners became the largest shareholder through common stock investment. Synergy Innovation invested in a convertible bond (CB) structure. If Synergy Innovation converts all of the convertible bonds in the future, it will secure the largest shareholder status of Neurobiogen.

This content was produced with the assistance of AI translation services.